Related Experiment Videos
[Gilles de la Tourette's syndrome]
A Damjanović1, V S Kostić, N Sternić
1Clinic for Neurology UCC, Belgrade.
Srpski Arhiv Za Celokupno Lekarstvo
|May 1, 1992
Summary
Gilles de la Tourette's syndrome (GTS) involves motor and vocal tics. Haloperidol showed a 64% therapeutic effect in treated GTS patients, offering a potential treatment avenue.
Area of Science:
- Neurology
- Psychiatry
Background:
- Gilles de la Tourette's syndrome (GTS) is a neurological disorder characterized by involuntary motor and vocal tics.
- It often presents with diverse behavioral comorbidities, impacting patients significantly.
Observation:
- The study observed 12 patients diagnosed with GTS, with a mean age of onset at 12.0 years.
- Diagnosis was delayed, occurring 9.5 years after symptom onset on average.
- Initial symptoms included motor or vocal tics in 11 out of 12 patients.
Findings:
- Fully developed GTS in patients included associated symptoms like coprolalia (6/12), echolalia, and copropraxia (2/12).
- High prevalence of attention deficits (9/12) and obsessive-compulsive disorders (8/12) were noted.
- Haloperidol demonstrated a 64% therapeutic efficacy in the treated patient cohort.
Implications:
- These findings highlight the complex presentation of GTS and the diagnostic delays.
- Neuroleptic therapy, specifically haloperidol, shows promise in managing GTS symptoms.
- Further research into effective management strategies for GTS comorbidities is warranted.